Volavka, Jan

The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes

Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology

Neurotransmitter Receptor Influence on BehaviorPharmacogenetics and Drug Metabolism

Cited by 769

Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism

Tiihonen, J., Hallikainen, T., Lachman, H., Saito, T., Volavka, J., Kauhanen, J., Salonen, J. T., Ryynänen, O.-P., Koulu, M., Karvonen, M. K., et al. (1999) · Molecular Psychiatry

Neurotransmitter Receptor Influence on BehaviorGenetic Associations and Epidemiology

Cited by 189

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

for the MEM-MD-29 Study Group, Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., & Gage, A. (2009) · Neuropsychopharmacology

Schizophrenia research and treatmentTreatment of Major Depression

Cited by 162

Profile of Mood States: the factors and their physiological correlates.

POLLOCK, V., CHO, D. W., REKER, D., & VOLAVKA, J. (1979) · The Journal of Nervous and Mental Disease

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesHeart Rate Variability and Autonomic Control

Cited by 143

Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies

Czobor, P., Van Dorn, R. A., Citrome, L., Kahn, R. S., Fleischhacker, W. W., & Volavka, J. (2015) · European Neuropsychopharmacology

Schizophrenia research and treatmentMedication Adherence and Compliance

Cited by 112